Evotec SE, headquartered in Hamburg, Germany, is a leading partner in drug discovery and development for the global pharmaceutical and biotechnology sectors. With a focus on a wide range of therapeutic areas including diabetes, oncology, and rare diseases, Evotec collaborates with major industry names like Bayer, Pfizer, and Takeda Pharmaceuticals. The company, which transitioned from Evotec AG to Evotec SE in 2019, leverages its expertise to advance treatments from concept to clinical development, aiming to address complex health challenges.
Three closed-end funds have quietly mailed monthly checks to investors for over two decades, yet most income seekers scroll right past them chasing bigger names with smaller payouts.
Most JEPI investors in taxable accounts don't realize how much of their monthly check quietly evaporates at tax time, and a 23-year-old closed-end fund built around a completely different income strategy is…
Kiplinger’s Personal Finance May 2026 letter makes it clear that if you are looking for yield, the door is wide open across the entire risk spectrum. We are seeing a massive spread,…
